Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Yale, Debiopharm partner to develop and commercialize Debio 1036 for inflammatory diseases

Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Yale University, a premier university with a long tradition of both basic and clinically directed biomedical research, announce an exclusive worldwide license agreement concerning the development and commercialization of Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory diseases.

4 May 2011

New MIT drug-delivery nanoparticle could target any type of tumor

MIT chemical engineers have designed a new type of drug-delivery nanoparticle that exploits a trait shared by almost all tumors: They are more acidic than healthy tissues.

4 May 2011

pSivida presents data of ILUVIEN Phase 3 trial in Diabetic Macular Edema at ARVO 2011

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the presentation of new data from the completed 36-month FAME Study of ILUVIEN for the treatment of Diabetic Macular Edema at the 2011 ARVO Annual Meeting.

4 May 2011

LSI announces publication of Emerging Medtech Companies report

Life Science Intelligence, a leading medical technology market intelligence firm, has announced the publication of its Report on Emerging Medtech Companies in Q1 2011.

30 Apr 2011

Pearl's PT003 Phase 2b study results in COPD to be presented at ATS meeting

Pearl Therapeutics Inc. announced today that complete results from the Company's Phase 2b study of PT003 in patients with moderate-to-very severe COPD will be presented during a late-breaker poster session at the upcoming annual meeting of the American Thoracic Society.

30 Apr 2011

Winner of MDEA Lifetime Achievement Award announced

UBM Canon's Medical Design Excellence Awards has announced the winner of the Medical Design Excellence Awards Lifetime Achievement Award. This award honors an individual whose contributions during a long career have had a demonstrable impact on technological, business, and cultural advancements in medical devices.

30 Apr 2011

ETP makes investment to support development of ICVrx's targeted epilepsy drug technology

Epilepsy Therapy Project, a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures, and ICVrx, LLC, a pharmacy product research and development company focused on novel therapies for central nervous system disorders, announced today that ETP has made an investment in ICVrx to support the development of ICVrx's targeted epilepsy drug technology for patients whose seizures are not controlled by current therapies.

30 Apr 2011

Celanese EVA Performance Polymers, PSI partner to develop drug-eluting devices

Particle Sciences Inc., a leading pharmaceutical CRO, and Celanese EVA Performance Polymers, a leading supplier of ethylene vinyl acetate into pharmaceutical applications, are working together to streamline the development of drug-eluting devices.

29 Apr 2011

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

Alkermes, Inc. today announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in opioid dependence have been published by The Lancet. The six-month, phase 3 trial met its primary endpoint and showed significantly greater opioid-free weeks among patients treated with VIVITROL, compared to placebo.

28 Apr 2011

Columbia requests FDA Priority Review for PROCHIEVE progesterone gel NDA

Columbia Laboratories, Inc., and Watson Pharmaceuticals, Inc., today announced that Columbia has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PROCHIEVE® (progesterone gel) for the reduction of risk of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy.

27 Apr 2011

Lilly and Medtronic’s joint venture in Parkinson’s disease therapy

Lilly has already developed a protein called GDNF (glial cell line derived neurotrophic factor) known to preserve the function of neurons and Medtronic will provide a system that carries the medicine to a key area of the brain.

From Medtronic 26 Apr 2011

FDA rules e-cigarettes as tobacco products and plans regulations

The Food and Drug Administration (FDA) has ruled that electronic cigarettes should be considered tobacco products. E-cigarettes are small plastic or metal devices that heat a liquid nicotine solution, creating a vapor that is then inhaled. They are marketed as a way to help smokers quit by addressing their addiction and the behavioral aspects of smoking.

26 Apr 2011

KemPharm to formulate and develop KP106 as oral film dosage for ADHD treatment

KemPharm, Inc. today announced that KP106, its clinical candidate for Attention Deficit/Hyperactivity Disorder, will be formulated and developed in an oral film dosage form pursuant to an exclusive collaboration agreement with MonoSol Rx relating to the development, commercialization and manufacture of KP106.

26 Apr 2011

A.P. Pharma targets resubmission of APF530 NDA in 2012

A.P. Pharma, Inc., a specialty pharmaceutical company, today provided an update on its lead product candidate, APF530, for the prevention of chemotherapy-induced nausea and vomiting (CINV).

25 Apr 2011

MonoSol Rx, KemPharm enter development and commercialization partnership for ADHD prodrug

MonoSol Rx, LLC, the developer of PharmFilm® drug delivery technology, today announced that the Company has entered into a development and commercialization partnership with KemPharm, a biopharmaceutical company focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease.

25 Apr 2011

Researchers package drug-loaded 'nanodisks' into vault nanoparticles for therapeutic drug delivery

There's no question, drugs work in treating disease. But can they work better, and safer?

22 Apr 2011

DEKRA, Health Canada clear ORTHOCON's new Absorbable Bone Hemostat Matrix

ORTHOCON, Inc., a privately-held therapeutic device company, today announced that DEKRA and Health Canada have cleared its HEMASORB Absorbable Bone Hemostat Matrix for clinical use and sale in Europe and Canada.

22 Apr 2011

TCI forecasts cancer vaccine market to approach $3 billion in 2015

Technology Catalysts International (TCI), leading global consultants to the pharmaceutical industry, announced that research on cancer trends and development has identified cancer vaccines as a viable treatment option for a variety of cancers that currently have ineffective treatments. The potential of the cancer vaccine market is forecast to approach $3 billion in 2015.

20 Apr 2011

Vyteris closes previously announced merger with MediSync BioServices

Vyteris, Inc. today announced that on April 6, 2011, the Company closed on its previously announced agreement to merge with MediSync BioServices, Inc., now a wholly owned subsidiary of Vyteris focused on the potential consolidation of high-value, niche contract research organizations (CRO), site management organizations (SMO) and related businesses within the $22 billion CRO industry.

18 Apr 2011

Nuvo Research to acquire ZARS Pharma

Nuvo Research Inc., a pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced that it has entered into an agreement to acquire ZARS Pharma, Inc., a specialty pharmaceutical company based in Salt Lake City, Utah.

18 Apr 2011